Beta Bionics, Inc. (BBNX)Healthcare | Medical Devices | Irvine, United States | NasdaqGM
16.95 USD
-0.08
(-0.470%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 17.68 +0.73 (4.307%) ⇧ (July 13, 2026, 4:23 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:34 a.m. EDT
The investment case for Beta Bionics remains fundamentally broken despite recent price stabilization. The company is burning cash aggressively, with operating cash flow of -$54.8 million and free cash flow of -$44 million, while posting a massive operating loss of nearly 88%. This is compounded by a deteriorating balance sheet where debt-to-equity sits at 2.55 and return on equity is negative 22.7%, signaling that capital is being destroyed rather than generated. Although revenue growth of 56.6% looks impressive on paper, it cannot mask the fact that the business is not yet profitable and is reliant on external funding. The lack of a dividend and the absence of a multi-year price history prevent any long-term 'buy and hold' thesis from forming. While the stock has recently rallied off its lows, the underlying economics suggest this is a speculative vehicle for high-risk capital rather than a stable investment. The options market reflects this tension, with heavy put buying at distant strikes acting as a hedge against potential failure or further dilution. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.168451 |
| AutoETS | 0.168453 |
| AutoTheta | 0.168701 |
| MSTL | 0.172289 |
| MSTL_72 | 0.358032 |
Forecast horizon: 60 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 4.80 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.171 |
| Excess Kurtosis | -1.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.548 |
| Revenue per Share | 2.508 |
| Market Cap | 755,320,768 |
| Forward P/E | -7.09 |
| Profit Margins | -60.27% |
| Website | https://www.betabionics.com |
As of July 11, 2026, 4:34 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put open interest at strikes like $30 and $10, suggesting a fear of a significant drop to lower levels. Conversely, there is notable call volume at deep out-of-the-money strikes ($30) and near-term ATM calls, indicating a split sentiment where some traders are betting on a sharp recovery while others are hedging against further downside. Implied volatility is elevated on short-dated puts relative to calls, reflecting immediate uncertainty.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.32735777 |
| Address1 | 11 Hughes |
| All Time High | 32.71 |
| All Time Low | 8.8 |
| Ask | 21.1 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 905,390 |
| Average Daily Volume3 Month | 966,727 |
| Average Volume | 966,727 |
| Average Volume10Days | 905,390 |
| Bid | 12.45 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 6.087 |
| City | Irvine |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.95 |
| Current Ratio | 10.693 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 17.51 |
| Day Low | 16.43 |
| Debt To Equity | 2.548 |
| Display Name | Beta Bionics |
| Earnings Call Timestamp End | 1,785,355,200 |
| Earnings Call Timestamp Start | 1,785,355,200 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,785,355,200 |
| Earnings Timestamp Start | 1,785,355,200 |
| Ebitda | -75,455,000 |
| Ebitda Margins | -0.68447 |
| Enterprise To Ebitda | -7.458 |
| Enterprise To Revenue | 5.105 |
| Enterprise Value | 562,712,704 |
| Eps Current Year | -2.10667 |
| Eps Forward | -2.39 |
| Eps Trailing Twelve Months | -1.37 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.8994 |
| Fifty Day Average Change | 4.050601 |
| Fifty Day Average Change Percent | 0.3140147 |
| Fifty Two Week Change Percent | 32.73578 |
| Fifty Two Week High | 32.71 |
| Fifty Two Week High Change | -15.759998 |
| Fifty Two Week High Change Percent | -0.4818098 |
| Fifty Two Week Low | 8.8 |
| Fifty Two Week Low Change | 8.150001 |
| Fifty Two Week Low Change Percent | 0.92613643 |
| Fifty Two Week Range | 8.8 - 32.71 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,738,247,400,000 |
| Float Shares | 25,345,355 |
| Forward Eps | -2.39 |
| Forward P E | -7.09205 |
| Free Cashflow | -44,055,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 420 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.57152003 |
| Gross Profits | 63,003,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0109 |
| Held Percent Institutions | 1.12621 |
| Implied Shares Outstanding | 44,561,695 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,025-01-30 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California. |
| Long Name | Beta Bionics, Inc. |
| Market | us_market |
| Market Cap | 755,320,768 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_365537151 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -66,439,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 758,885,665 |
| Number Of Analyst Opinions | 11 |
| Open | 17.12 |
| Operating Cashflow | -54,782,000 |
| Operating Margins | -0.87856 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 949 427 7785 |
| Post Market Change | 0.72999954 |
| Post Market Change Percent | 4.306782 |
| Post Market Price | 17.68 |
| Post Market Time | 1,783,974,215 |
| Previous Close | 17.03 |
| Price Eps Current Year | -8.045874 |
| Price Hint | 2 |
| Price To Book | 2.7846231 |
| Price To Sales Trailing12 Months | 6.851728 |
| Profit Margins | -0.60269 |
| Quick Ratio | 9.385 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.63636 |
| Region | US |
| Regular Market Change | -0.0799999 |
| Regular Market Change Percent | -0.469759 |
| Regular Market Day High | 17.51 |
| Regular Market Day Low | 16.43 |
| Regular Market Day Range | 16.43 - 17.51 |
| Regular Market Open | 17.12 |
| Regular Market Previous Close | 17.03 |
| Regular Market Price | 16.95 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,010,836 |
| Return On Assets | -0.15042 |
| Return On Equity | -0.22714001 |
| Revenue Growth | 0.566 |
| Revenue Per Share | 2.508 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 44,561,695 |
| Shares Percent Shares Out | 0.153 |
| Shares Short | 6,819,825 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,199,951 |
| Short Name | Beta Bionics, Inc. |
| Short Percent Of Float | 0.1538 |
| Short Ratio | 6.14 |
| Source Interval | 15 |
| State | CA |
| Symbol | BBNX |
| Target High Price | 32.0 |
| Target Low Price | 13.0 |
| Target Mean Price | 19.18182 |
| Target Median Price | 18.0 |
| Total Cash | 199,520,000 |
| Total Cash Per Share | 4.477 |
| Total Debt | 6,912,000 |
| Total Revenue | 110,238,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.96205 |
| Two Hundred Day Average Change | -1.0120487 |
| Two Hundred Day Average Change Percent | -0.056343723 |
| Type Disp | Equity |
| Volume | 1,010,836 |
| Website | https://www.betabionics.com |
| Zip | 92,618 |